Home

Lota S. Zoth

CIK 1278219 · CHIEF SCIENTIFIC OFFICER · last filed 2026-06-17

Lota S. Zoth is a CHIEF SCIENTIFIC OFFICER who has filed 66 SEC Form 4 insider transactions across 11 companies since 2007. The most recent filing, for ENGNW, was dated Jun 17, 2026. Across all open-market trades the lifetime net is −$84.0K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $87.9K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$87.9K

Companies

11

Total Filings

66

Lifetime Open-Market Net

-$84.0K

Filer Profile

Reported Address
334 CR 692
BUFFALO GAP, TX 79508
Formerly Known As
ZOTH LOTA S (2004–2007)
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ENGNW Director — $0.23 — $0 4 2026-06-17
INO Director 8,726 $1.25 $10.9K -$37.8K 15 2026-05-21
FFIN Director 2,142 $33.16 $71.0K $0 1 2026-05-05
89bio, Inc. (ETNB) Delisted Director — $14.84 — $0 7 2025-10-30
LUMOS PHARMA, INC. (LUMO) Delisted Director 0 $4.34 $0 $0 6 2024-12-13
ZYME Director — $26.24 — $0 4 2022-12-23
LUMOS PHARMA, INC. (NLNK) Delisted Director 1,112 — — $0 11 2020-01-06
Spark Therapeutics, Inc. (ONCE) Delisted CHIEF SCIENTIFIC OFFICER 0 — — $0 6 2019-12-17
Orexigen Therapeutics, Inc. (OREX) Delisted Director — — — $0 6 2017-07-18
HYPERION THERAPEUTICS INC (HPTX) Delisted Director 0 — — $0 2 2015-05-08
MEDI SVP, Chief Financial Officer 178 $33.38 $5.9K -$46.2K 3 2007-06-19

Recent Filings

66 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-17 ENGNW Grant (A) — $0 EDGAR
2026-05-21 INO Grant (A) — $0 EDGAR
2026-05-05 FFIN Grant (A) +2,142 $0 EDGAR
2025-10-30 89bio, Inc. (ETNB) Delisted Disp (D) — $0 EDGAR
2025-06-16 ENGNW Grant (A) — $0 EDGAR
2025-05-21 INO Exer (M) +2,167 $0 EDGAR
2025-02-05 89bio, Inc. (ETNB) Delisted Grant (A) — $0 EDGAR
2024-12-13 LUMOS PHARMA, INC. (LUMO) Delisted Disp (D) −2,187 $0 EDGAR
2024-06-18 ENGNW Grant (A) — $0 EDGAR
2024-06-07 LUMOS PHARMA, INC. (LUMO) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 66
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.